334 related articles for article (PubMed ID: 17503984)
1. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
[TBL] [Abstract][Full Text] [Related]
2. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
3. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.
Denys D; van Megen HJ; van der Wee N; Westenberg HG
J Clin Psychiatry; 2004 Jan; 65(1):37-43. PubMed ID: 14744166
[TBL] [Abstract][Full Text] [Related]
4. Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Affect Disord; 2006 Mar; 91(1):39-44. PubMed ID: 16443280
[TBL] [Abstract][Full Text] [Related]
5. Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder.
Denys D; Fluitman S; Kavelaars A; Heijnen C; Westenberg HG
Psychoneuroendocrinology; 2006 Apr; 31(3):355-60. PubMed ID: 16249058
[TBL] [Abstract][Full Text] [Related]
6. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.
Denys D; van Megen H; Westenberg H
J Clin Psychiatry; 2002 Aug; 63(8):700-3. PubMed ID: 12197450
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Albert U; Aguglia E; Maina G; Bogetto F
J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
[TBL] [Abstract][Full Text] [Related]
10. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.
Denys D; Burger H; van Megen H; de Geus F; Westenberg H
Int Clin Psychopharmacol; 2003 Nov; 18(6):315-22. PubMed ID: 14571151
[TBL] [Abstract][Full Text] [Related]
11. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
[TBL] [Abstract][Full Text] [Related]
12. The role of venlafaxine in the treatment of obsessive-compulsive disorder.
Phelps NJ; Cates ME
Ann Pharmacother; 2005 Jan; 39(1):136-40. PubMed ID: 15585743
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
14. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
15. Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder.
Tenney NH; Denys DA; van Megen HJ; Glas G; Westenberg HG
Int Clin Psychopharmacol; 2003 Jan; 18(1):29-33. PubMed ID: 12490772
[TBL] [Abstract][Full Text] [Related]
16. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
17. Venlafaxine in treatment-resistant obsessive-compulsive disorder.
Hollander E; Friedberg J; Wasserman S; Allen A; Birnbaum M; Koran LM
J Clin Psychiatry; 2003 May; 64(5):546-50. PubMed ID: 12755657
[TBL] [Abstract][Full Text] [Related]
18. [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes].
Zhang L; Liu X; Li T; Yang Y; Hu X; Collier D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct; 21(5):479-81. PubMed ID: 15476175
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.
Pollack M; Mangano R; Entsuah R; Tzanis E; Simon NM; Zhang Y
Psychopharmacology (Berl); 2007 Oct; 194(2):233-42. PubMed ID: 17589833
[TBL] [Abstract][Full Text] [Related]
20. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
